1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213–1220. PMID:
10534170.
2. Rubin BP, Fletcher JA, Fletcher CD. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. Int J Surg Pathol 2000;8:5–10. PMID:
11493959.
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466–1478. PMID:
17090188.
4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813–3825. PMID:
15365079.
5. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–580. PMID:
9438854.
6. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–4349. PMID:
14645423.
7. Sleijfer S, Wiemer E, Verweij J. Drug insight: gastrointestinal stromal tumors (GIST); the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 2008;5:102–111. PMID:
18235442.
8. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–58. PMID:
10636102.
9. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383–389. PMID:
11296107.
12. Park KC, Kim HC, Park IJ, Yu CS, Kim JS, Kim JC. Clinicopathologic and immunohistochemical features of gastrointestinal stromal tumors (GISTs) in the colon & rectum. J Korean Soc Coloproctol 2004;20:371–377.
13. Choi SH, Kim SJ, Choi YJ, Min BS, Kim JS, Baik SH, et al. Clinicopathologic analysis of gastrointestinal stromal tumors of the colon and rectum. J Korean Soc Coloproctol 2009;25:323–333.
14. Paek OJ, Kim YB, Oh SY, Suh KW. Gastrointestinal stromal tumors of the colon and rectum. J Korean Soc Coloproctol 2009;25:318–322.
15. Kang YK, Kim KM, Sohn T, Choi D, Kang HJ, Ryu MH, et al. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. J Korean Med Sci 2010;25:1543–1552. PMID:
21060741.
16. Rossi CR, Mocellin S, Mencarelli R, Foletto M, Pilati P, Nitti D, et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer 2003;107:171–176. PMID:
12949790.
17. Dematteo RP, Gold JS, Saran L, Gonen M, Liau KH, Maki RG, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008;112:608–615. PMID:
18076015.
18. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626–632. PMID:
18235122.
19. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–480. PMID:
12181401.
20. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097–1104. PMID:
19303137.
22. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4): 64–67. PMID:
19454466.
24. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14–24. PMID:
17072676.
25. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764–4774. PMID:
16954519.
26. Baik SH, Kim NK, Lee CH, Lee KY, Sohn SK, Cho CH, et al. Gastrointestinal stromal tumor of rectum: a reoport of 7 cases. J Korean Surg Soc 2005;68:117–122.
28. Bonvalot S, Eldweny H, Pechoux CL, Vanel D, Terrier P, Cavalcanti A, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006;13:1596–1603. PMID:
16957966.
29. Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006;93:304–311. PMID:
16496358.